Experimental combo aims to boost immune attack on Hard-to-Treat head and neck cancer
Disease control
Not yet recruiting
This early-phase study tests a combination of two drugs—decitabine (a chemotherapy that can 'reawaken' genes) and nivolumab (an immunotherapy that helps the immune system fight cancer)—in people with head and neck cancer that has returned or spread and cannot be cured with local …
Phase: PHASE1 • Sponsor: Kyunghee Burkitt, DO, PhD • Aim: Disease control
Last updated May 01, 2026 15:59 UTC